Publications by authors named "Piyush Gugale"
Prevalence of co-existent COVID-19-associated pulmonary aspergillosis (CAPA) and its impact on early mortality in patients with COVID-19-associated pulmonary mucormycosis (CAPM).
Valliappan Muthu Ritesh Agarwal Shivaprakash Mandya Rudramurthy Deepak Thangaraju Manoj Radhakishan Shevkani Piyush Gugale
Mycoses
May 2024
Article Synopsis
- A study analyzed mixed mould infections in patients with COVID-19-associated pulmonary mucormycosis (CAPM) to determine the prevalence of co-existing COVID-19-associated pulmonary aspergillosis (CAPA) and its impact on early mortality.
- Among 105 patients with CAPM, 20% had mixed mould infections, and those with CAPA experienced significantly higher early mortality rates (42.9%) compared to those without (17.9%).
- The findings suggest that co-existing CAPA worsens the prognosis for CAPM patients, highlighting the need for further research on mixed mould infections globally.
Article Synopsis
- The study aims to compare COVID-19-associated pulmonary mucormycosis (CAPM) with COVID-19-associated rhino-orbital mucormycosis (CAROM), identify factors linked to CAPM, and determine 12-week mortality predictors in CAPM patients.
- Researchers conducted a retrospective analysis involving 1724 COVID-19 patients, assessing demographics and illness details, and found that CAPM had higher rates of male sex, hypoxemia, and certain health conditions compared to CAROM.
- Results showed that CAPM had higher 12-week mortality (52.3%) than CAROM (30.5%), with factors like hypoxemia and Aspergillus co-infection increasing mortality risk, while
We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls.
View Article and Find Full Text PDF